awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38366755-E585C76F-CE10-4204-8F4C-49A88F0F6A83
Q38366755-E585C76F-CE10-4204-8F4C-49A88F0F6A83
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38366755-E585C76F-CE10-4204-8F4C-49A88F0F6A83
Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer.
P2860
Q38366755-E585C76F-CE10-4204-8F4C-49A88F0F6A83
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38366755-E585C76F-CE10-4204-8F4C-49A88F0F6A83
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
1f7ca42d0c97a07afa0f2f7f0e7489908c8d2ad4
P2860
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.